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Abstract – L-a-glycerophosphate oxidase (GlpO) plays a central role in virulence of Mycoplasma
mycoides subsp. mycoides SC, a severe bacterial pathogen causing contagious bovine pleuropneumonia
(CBPP). It is involved in production and translocation of toxic H2O2 into the host cell, causing inﬂammation
and cell death. The binding site on GlpO for the cofactor ﬂavin adenine dinucleotide (FAD) has been
identiﬁed as Gly12Gly13Gly14Ile15Ile16Gly17. Recombinant GlpO lacking these six amino acids
(GlpODFAD) was unable to bind FAD and was also devoid of glycerophosphate oxidase activity, in contrast
to non-modiﬁed recombinant GlpO that binds FAD and is enzymatically active. Polyclonal monospeciﬁc
antibodies directed against GlpODFAD, similarly to anti-GlpO antibodies, neutralised H2O2 production of
M. mycoides subsp. mycoides SC grown in the presence of glycerol, as well as cytotoxicity towards
embryonic calf nasal epithelial (ECaNEp) cells. The FAD-binding site of GlpO is therefore suggested as a
valuable target site for the future construction of deletion mutants to yield attenuated live vaccines of
M. mycoides subsp. mycoides SC necessary to efﬁciently combat CBPP.
CBPP / L-a-glycerophosphate oxidase / FAD-binding site / targeted deletion mutant / neutralizing
antibody
1. INTRODUCTION
Glycerol metabolism is described to play a
central role in virulence of Mycoplasma myco-
ides subsp. mycoides SC, the etiological agent
of contagious bovine pleuropneumonia (CBPP)
[4, 13, 14, 20], as well as in Mycoplasma pneu-
moniae [9]. Glycerol at physiological concen-
trations is incorporated and phosphorylated to
obtain a-glycerol-3-phosphate (G3P) by M. my-
coides subsp. mycoides SC via the highly active
ATP-dependent glycerol transporter system
GtsABC and then further metabolised to dihy-
droxyacetone phosphate (DHAP) in the pres-
ence of oxygen by the L-a-glycerophosphate
oxidase (GlpO, also named a-glycerol-3-phos-
phate oxidase) with the release of the highly
toxic compound hydrogen peroxide H2O2
[20]. Scattered electron microscopy and Triton
X-114 partitioning revealed GlpO to be mem-
brane-located in M. mycoides subsp. mycoides
SC with a signiﬁcant part of the protein being
surface-exposed [13], which explains the fact
that the mycoplasma is able to release signiﬁ-
cant amounts of H2O2 into the growth medium.
Using a cell culture infection model for
M. mycoides subsp. mycoides SC it was shown
thatH2O2isnotonlyreleasedbythemycoplasma
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cells causing cytotoxicity and cell death [13].
M. mycoides subsp. mycoides SC strains gener-
ally possess the glycerol ABC transporter
GtsABC for the assimilation of glycerol with
the exception of strains from recent European
outbreaks (period 1980–1999) producing sig-
niﬁcantly lower amounts of H2O2 [8, 20]a n d
showing a very low cytotoxicity level towards
eukaryotic host cells in the presence of glycerol
compared to most otherstrains[4, 13].Blocking
the L-a-glycerophosphate oxidase GlpO by
monospeciﬁc anti-GlpO antibodies hampers the
production and release of H2O2 and concomi-
tantlyinhibitscytotoxicityofM.mycoidessubsp.
mycoides SC towards embryonic calf nasal epi-
thelial (ECaNEp) cells [13]. These results indi-
cate that GlpO may act as a useful antigen
target to induce protective immunity against
CBPP.
Furthermore, since GlpO-promoted H2O2
production is a central virulence attribute of
M. mycoides subsp. mycoides SC, the glpO
gene represents an ideal target for mutations
in order to better attenuate vaccine strains,
whose residual virulence is of concern. In this
respect, it has to be mentioned that the live vac-
cine strains T1/44 and T1/Sm are currently used
to vaccinate against CBPP [18]. However, both
vaccines have been shown to contain a fully
active glycerol transport system GtsABC and
an enzymatically active L-a-glycerophosphate
oxidase GlpO, which results in the release of
signiﬁcant amounts of H2O2 in the presence
of physiological concentrations of glycerol [4,
21] and cytotoxicity against ECaNEp cells
[4]. This feature might be the cause of
unwanted side reactions encountered with these
vaccines [17] and of CBPP elicitation in cattle
upon inoculation of T1-derived vaccines via
the endobronchial route [11].
In the current work, we studied the basic,
structural and functional features of GlpO of
M. mycoides subsp. mycoides SC with the
aim of identifying mutation sites in the glpO
gene for future live vaccine development. In
this view, the mutations should result in (i) loss
of H2O2-producing enzymatic activity;
(ii) attenuation of currently used vaccines; and
(iii) preservation of the antigenic properties of
GlpO required to elicit neutralising antibodies
like those induced by native GlpO [13]. GlpO
(EC 1.1.3.21) is an enzyme that belongs to
the family of oxidoreductases, speciﬁcally those
acting on the CH-OH group of the donor with
oxygen as the acceptor. It employs one cofactor,
ﬂavin adenine dinucleotide (FAD). In biochem-
istry, FAD is a redox cofactor involved in sev-
eral important metabolic reactions. FAD can
exist in two different redox states and its bio-
chemical role usually involves alternating
between these two states. FAD can be reduced
to FADH2, whereby it accepts two hydrogen
atoms. FADH2 is an energy-carrying molecule,
and the reduced coenzyme can be utilised as a
substrate for oxidative phosphorylation. FADH2
is re-oxidised to FAD, which makes it possible
to produce two moles of the universal energy
carrier ATP. The ADP portion of FAD interacts
mostly via residues from the ﬁrst b-strand–
a-helix–b-strand (bab)f o l di nt h eN - t e r m i n a l
portion of GlpO, which includes the Gly-
X-Gly-X-X-Gly ﬁngerprint that interacts with
the diphosphate moiety of FAD [7].
The present study investigated the function
of recombinant GlpO from M. mycoides subsp.
mycoides SC, determining the FAD-binding site
and the potential of mutant GlpODFAD, i.e.,
the recombinant GlpO without the FAD-bind-
ing site Gly12-Gly13-Gly14-Ile15-Ile16-Gly17,t o
induce antibodies neutralising cytotoxicity of
M. mycoides subsp. mycoides SC.
2. MATERIALS AND METHODS
2.1. Strains, growth conditions
and DNA extraction
M. mycoides subsp. mycoides SC strain Afade ´,
a highly virulent ﬁeld strain isolated in 1968 in
Cameroon, was used for the virulence studies unless
otherwise stated. Mycoplasmal cultures were grown
in a standard mycoplasma medium (Axcell Biotech-
nologies, St. Genis-L’Argentie `re, France) at 37  C
to a density of approximately 5 · 10
8 cells per mL.
For genetic manipulation and subcloning, Esche-
richia coli strains DH5a and BL21(DE3) were used.
The pETHIS-1 expression vector [15] was used for
expression of recombinant N- and C-terminal poly-
histidine fusion proteins.
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ECaNEp cells were prepared from foetuses
obtained from a local abattoir and were maintained
in minimal essential medium (MEM)-Earle medium
supplementedwith7%foetal calfserum andpenicillin
(100 IU/mL) in 24-well microtiter plates and used at a
conﬂuent density of 2 · 10
5cells per well, at 37  Ci n
a humidiﬁed 5% CO2 atmosphere [13]. Foetal calf
serumandcellculturemediawerepurchasedfromSer-
omed (Biochrom, Munich, Germany). The cells were
routinely screened for contamination by mycoplasmas
using PCR or for contamination by bovine viral diar-
rhoea virus using immunostaining [16].
2.3. Bioinformatics
Comparison of the GlpO protein sequence of
strain Afade ´ with the EMBL/GenBank database
was performed using the BLAST program blastp [1].
The PSIPRED Protein Structure Prediction Server
v2.6 [12] was used to predict the secondary structure
of GlpO of strain Afade ´.
Since no 3D structures are annotated in the 3D
databases for GlpO of M. mycoides subsp. mycoides
SC, a search for 3D domains for bacterial GlpO
sequences within available sequences from the NCBI
site was performed. Among the 14 GlpO structures
found, L-a-glycerophosphate oxidase 2RGH:A from
Streptococcus [7] was selected for comparison with
the GlpO of M. mycoides subsp. mycoides SC. The
3D-Mol Viewer software from the Vector NTI
Advance 10.3.0 package (Invitrogen AG, Basel,
Switzerland) was used to display the 3D protein
structure model of 2RGH:A with its FAD molecule.
The SWISS-MODEL software [2], accessible via
the ExPASy web server, was used to display GlpO
of M. mycoides subsp. mycoides SC taking 2RGH:A
from Streptococcus as the template.
2.4. Cloning and expression of recombinant
proteins
The glpO gene of M. mycoides subsp. mycoides
strain Afade ´ was ﬁrst ampliﬁed with the primers
Afade ´_EcoRI and MmmSC_GlpO_BamHI (Tab. I)
containing the restriction sites for EcoRI and BamHI,
respectively. As a template for PCR ampliﬁcation,
plasmid pETHIS-1::glpO containing mutagenised
TGGTrp codons in the glpO gene [13]w a su s e d .T h e
pETHIS-1 vector was ampliﬁed with the primers
pETHIS-1_EcoRI and pETHIS-1_BamHI (Tab. I)t o
give the linearised vector pETHIS-1m harbouring
EcoRI and BamHI restriction sites. This procedure
wasusedtocreateGlpOfusionwithapolyhistidinetail
attheC-terminusonly.PuriﬁedrecombinantGlpOcar-
rying the 10xHis-tagged C-terminus was shown to be
enzymaticallymoreactiveundertheinvitroconditions
used in this study compared to GlpO with polyhisti-
dine tags at both N-terminal and C-terminal ends.
The codons for the putative FAD-binding site
Gly12-Gly13-Gly14-Ile15-Ile16-Gly17 on glpO were
removed using the overlap extension-PCR method
[5]t oo b t a i nt h eglpODFAD gene. The codons for
the putative FAD-binding site located at nucleotides
(nt) 34–51 downstream of the ATG start codon of
the glpO sequence of strain Afade ´w i t hE M B L /
GenBank accession number AJ581566 were removed
subsequently with (i) primer pair MmmSC_glpO_
FAD1F and MmmSC_glpO_FAD1R (Tab. I)t o
removebases34–39codingfor Gly12-Gly13,followed
by (ii) primer pair MmmSC_glpO_FAD2F and
MmmSC_glpO_FAD2R (Tab. I)t or e m o v e
bases 40–45 coding for Gly14-Ile15, and (iii) primer
pair MmmSC_glpO_FAD3F and MmmSC_glpO_
FAD3R (Tab. I) to remove bases 46–51 coding
for Ile16-Gly17. The products were cloned into
pETHIS-1m by ﬂanking EcoRI and BamHI cleavage
sites. The constructs were analysed by DNA sequenc-
ing and the ﬁnal clone was introduced into E. coli
BL21(DE3) for expression. The expression of the
cloned glpODFAD gene was induced by the addition
of 1 mM IPTG at mid-exponential phase and further
incubation for 4 h at 30  C. Following induction, the
polyhistidine-tailed fusion protein GlpODFAD was
puriﬁed via Ni
2+ chelation chromatography on a Ni-
NTAcolumnunderdenaturingconditionsasdescribed
previously for other proteins [15, 19]. The fractions
were dialysed and analysed on SDS-10% polyacryl-
amide gels.
Immunoblot analysis with mouse anti-His anti-
body (GE Healthcare, Otelﬁngen, Switzerland) (at a
dilution of 1:3000) was carried out by standard meth-
ods [3], using SDS-10% polyacrylamide gels for sep-
aration of the proteins, which were blotted onto
nitrocellulose membranes. Phosphatase-labelled con-
jugate goat anti-mouse immunoglobulin G (heavy
plus light chains) (Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA) at a dilution of 1:2000 was
used for the visualisation of recombinant, polyhisti-
dine-tailed proteins on blots.
2.5. In vitro activity assay
Both recombinant, polyhistidine-tailed proteins
GlpO and GlpODFAD were also puriﬁed under
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activity. For this purpose, E. coli BL21(DE3) cells
expressing the recombinant protein GlpO were sus-
pended in buffer A (50 mM NaH2PO4,3 0 0 m M
N a C l ,1 0m Mi m i d a z o l e ,p H8 . 0 )f o l l o w e db ys o n i ﬁ -
cation in a Branson Soniﬁer and binding for 1 h at
4  C to Ni-NTA beads. The beads were then washed
with buffer C (50 mM NaH2PO4, 300 mM NaCl,
20 mM imidazole, pH 8.0) and eluted with buffer
D (50 mM NaH2PO4, 300 mM NaCl, 250 mM imid-
azole, pH 8.0). Recombinant GlpODFAD was puri-
ﬁed by suspending the corresponding IPTG-induced
E. coli cells in buffer B (50 mM NaH2PO4,
300 mM NaCl, 1 mM imidazole, pH 6.5) followed
b ys o n i ﬁ c a t i o ni naB r a n s o nS o n i ﬁ e ra n db i n d i n g
for 1 h at 4  C to Ni-NTA beads. The beads were
then washed with buffer B and eluted with buffer
D. The fractions were analysed on SDS-10% poly-
acrylamide gels.
The activities of puriﬁed recombinant proteins
GlpO and GlpODFAD were measured by their ability
to produce H2O2 in the presence of glycerol. The
activity assay was performed in the presence of ﬁl-
ter-sterilised incubation buffer (67.7 mM HEPES,
1 4 0m MN a C l ,7m MM g C l 2,p H7 . 3 )s u p p l e m e n t e d
w i t h9m MA T P ,6 5n MF A Da n d6m Ma-glycerol-
3-phosphate (G3P), to which recombinant GlpO or
recombinant GlpODFAD was added at a ﬁnal
20 lg/mL concentration. The production of H2O2
was measured with the peroxide test (Merck KgaA,
Darmstadt, Germany) as described previously [20].
2.6. Fluorescence measurements
Fluorescence excitation and emission spectra of
the proteins was measured with a Perkin-Elmer
LS50 dual wavelength ﬂuorescence spectrophotome-
ter. The emission spectrum (370–600 nm) at an exci-
tation wavelength of 350 nm and the excitation
spectrum (250–410 nm) at an emission wavelength
of 430 nm were recorded as described previously [6].
2.7. Sera, polyclonal antibodies
and immunoglobulin puriﬁcation
Immune sera directed against recombinant GlpO
or GlpODFAD were obtained by subcutaneous
immunisation of rabbits with 80 lgo fp u r i ﬁ e d
recombinant polyhistidine-tailed proteins in 500 lL
of phosphate-buffered saline (PBS) buffer (50 mM
Na2HPO4/NaH2PO4,1 4 0m MN a C l ,p H8 . 0 ) ,m i x e d
with 500 lL of Adjuvant 10 (Gerbu Biotechnik
GmBH, Gaiberg, Germany). Primary immunisation
was followed by booster injections with 80 lgo f
the respective protein 2 and 4 weeks later. The rabbits
were bled 21 days after the last booster immunisa-
tion. Antisera were prepared from the blood samples
and stored at 20  C.
Immunoglobulin G (IgG) fractions from decom-
plemented rabbit anti-GlpO and anti-GlpODFAD sera
were puriﬁed with the HiTrap Protein G kit (Amer-
sham Pharmacia Biotech, Uppsala, Sweden) as direc-
ted by the manufacturer. Protein concentrations were
determined using a NanoDrop ND-1000 spectropho-
tometer (Witec AG, Littau, Switzerland).
2.8. Quantiﬁcation of H2O2 and inhibition assay
To measure H2O2 production, strains of M. myco-
ides subsp. mycoides SC were grown in mycoplasma
culture medium for 3 days at 37  Ct oad e n s i t yo f
approximately 5 · 10
8 cells/mL. The culture was cen-
trifuged at 8 000 · g for 10 min at 4  C, washed
Table I. Oligonucleotide primers.
Primer Sequence (5’–3’)
a
Afade ´_EcoRI GATCgaattcATGAAGCAAACAAAAGTTGATATTTG
MmmSC_GlpO_BamHI ATATggatccTTTCCATGGAAGAATAGCTTC
MmmSC_glpO_FAD1F GATATTTGTATCATTGGAATTATTGGTGCTTCTGTTGCAAGAGAA
MmmSC_glpO_FAD1R AGCACCAATAATTCCAATGATACAAATATCAACTTTTGTTTGCTT
MmmSC_glpO_FAD2F GATATTTGTATCATTATTGGTGCTTCTGTTGCAAGAGAACTAGCA
MmmSC_glpO_FAD2R AACAGAAGCACCAATAATGATACAAATATCAACTTTTGTTTGCTT
MmmSC_glpO_FAD3F GATATTTGTATCATTGCTTCTGTTGCAAGAGAACTAGCAAAATTT
MmmSC_glpO_FAD3R TCTTGCAACAGAAGCAATGATACAAATATCAACTTTTGTTTGCTT
pETHIS-1_EcoRI GATCgaattcTCTCCTTCTTAAAGTTAAACAAAA
pETHIS-1_BamHI ATATggatccCACCATCACCATCACCATC
a Lower-case letters indicate nucleotides added to create restriction enzyme recognition sites for cloning.
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warmed incubation buffer at 37  Ca tad e n s i t yo f
10
9 cells/mL, portioned in aliquots of 1 mL, and
incubated at 37  Cf o r1h .T oi n d u c eH 2O2 produc-
tion, glycerol was added to the mycoplasma suspen-
sions at a ﬁnal concentration of 100 lM, representing
the physiological concentration of glycerol in bovine
serum. The production of H2O2 was measured with
the peroxide test (Merck KgaA) as described previ-
ously [20] at time zero and 1, 2, 5, 10, 20
and 40 min after the addition of glycerol. In order
to measure the inhibitory potential of anti-GlpO or
anti-GlpODFAD antibodies, mycoplasmas were pre-
treated with IgG preparations of either anti-GlpO or
anti-GlpODFAD antiserum at concentrations of 10
lg/mL for 30 min at 37  C, followed by two washes
with PBS buffer.
2.9. Detection of translocation of H2O2 from
infecting mycoplasmas into ECaNEp cells
To monitor intracellular H2O2 and accompanying
reactive oxygen species (ROS) in ECaNEp cells, the
formation of dichloroﬂuorescein derivatives after
cleavage of the ester groups of nonﬂuorescent 5
(and 6)-chloromethyl-2’,7’-dichlorodihydroﬂuoresce-
in diacetate-acetyl ester (CM-H2DCFDA; Molecular
Probes, Eugene, OR, USA) by H2O2-dependent oxi-
dation was measured as already described [13]. The
ECaNEp cells were incubated for 1 h with 10 lM
CM-H2DCFDA and washed once with MEM-Earle
medium. Cells were then infected with M. mycoides
subsp. mycoides SC strain Afade ´ at a multiplicity
of infection (MOI) of 500 mycoplasmas per cell in
the presence or absence of 100 lM glycerol. To
assess blocking of the GlpO activity, M. mycoides
subsp. mycoides SC cells were pre-treated with
anti-GlpO or anti-GlpODFAD IgG at 8 to 28 lg/mL.
Intracellular H2O2 was monitored 20 min after infec-
tion with mycoplasmas by ﬂuorescence microscopy
using a Nikon Eclipse TE 300 microscope. Note that
all steps involving CM-H2DCFDA, including
handling of this chemical, were performed in the
dark.
3. RESULTS
3.1. FAD-binding site Gly-X-Gly-X-X-Gly
of GlpO
The results obtained with the BLAST
program blastp showed that the 387-aa GlpO
of M. mycoides subsp. mycoides SC strain
Afade ´ (EMBL/GenBank accession number
CAE46342) has strong homologies to several
bacterial glycerol-3-phosphate oxidases and
glycerol-3-phosphate dehydrogenases. In some
cases, these similar proteins are larger than
450 aa in length and the GlpO-homologous
portions reside in their N-termini (not shown).
The secondary structure prediction of GlpO
of strain Afade ´ indicates the presence of a
bab fold in its N-terminal portion, which
includes the Gly-Gly-Gly-Ile-Ile-Gly ﬁngerprint
that is assumed to interact with the diphosphate
moiety of FAD (Fig. 1). A comparison with
protein 2RGH:A, the L-a-glycerophosphate
oxidase from Streptococcus [7], demonstrated
the presence of two putative G3P-binding sites
also in GlpO from M. mycoides subsp. myco-
ides SC. They are located in the region
spanning aa residues 310–350, close to the
C-terminus (Fig. 1).
Protein 2RGH:A, whose 3D structure is
known, was chosen as a model to envisage
the possible 3D structure of GlpO from M. my-
coides subsp. mycoides SC. 2RGH:A showed
the three Gly residues in the Gly-X-Gly-X-X-
Gly ﬁngerprint (in this case Gly39-Gly40-
Gly41-Ile42-Thr43-Gly44)i nabab fold in the
vicinity of the diphosphate moiety of FAD
(Fig. 2A), which corresponds to the putative
FAD-binding site Gly12-Gly13-Gly14-Ile15-
Ile16-Gly17 in the GlpO of M. mycoides subsp.
mycoides SC strain Afade ´( Fig. 2B).
3.2. Structural properties and enzymatic
activity of recombinant GlpO
and GlpODFAD
Immunoblot analysis of recombinant pro-
teins GlpO and GlpODFAD, both carrying a
10xHis-tagged C-terminus, with anti-His anti-
bodies revealed two protein bands of 45 and
90 kDa for GlpO and one single protein band
of 44 kDa for GlpODFAD (Fig. 3A). Both
polyclonalmonospeciﬁcanti-recombinantGlpO
and GlpODFAD sera strongly reacted with a
43-kDa protein and poorly reacted with 85-
and 125-kDa proteins from total antigen of
M. mycoides subsp. mycoides SC strain
Afade ´( Fig. 3B).
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(page number not for citation purpose) Page 5 of 12Figure 1. Secondary structure of GlpO of M. mycoides subsp. mycoides SC strain Afade ´. Boxes represent
FAD-binding (red) and putative G3P-binding (blue) segments, as deﬁned previously [7]. Yellow arrows and
green cylinders represent b-sheets and a-helices, respectively, as obtained by the protein structure prediction
program PSIPRED. (For a colour version of this ﬁgure, please consult www.vetres.org.)
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Page 6 of 12 (page number not for citation purpose)Figure 2. Three-dimensional model showing the FAD-binding site of GlpO. The ‘‘ball and stick’’ views
were obtained with the 3D-Mol Viewer program to display: (A) the predicted structure model of the FAD-
binding site of 2RGH:A of Streptococcus [7] and its bound FAD molecule (‘‘stick’’ view); and (B) the
SWISS-MODEL-simulated structure of the FAD-binding site of GlpO of M. mycoides subsp. mycoides SC
strain Afade ´ obtained by taking 2RGH:A from Streptococcus as the template (FAD is not displayed by
SWISS-MODEL-generated structure simulation). The protein chains (excluding the FAD-binding sites Gly-
X-Gly-X-X-Gly) are illustrated as blue wires. The displayed FAD molecule is shown in red and the amino
acids X of the FAD-binding sites are shown in blue while their three amino acids Gly are displayed in
yellow. (For a colour version of this ﬁgure, please consult www.vetres.org.)
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binant proteins GlpO and GlpODFAD were
puriﬁed under native conditions and tested for
their functional and enzymatic activities. A ﬁnal
concentrationof20 lg/mLforbothrecombinant
proteins was used in the assays. Under in vitro
conditions, recombinant GlpO of M. mycoides
subsp. mycoides SC oxidised G3P with release
of 2 lg/mL H2O2 into the assay solution after
10 min incubation and 10 lg/mL H2O2 after
40 min incubation. In contrast, recombinant
GlpODFAD showed no release of H2O2 into
the assay solution.
3.3. Spectroscopic analysis of GlpO
and GlpODFAD
It was observed that cell lysates of GlpO-
producing E. coli had a yellowish appearance,
whereas cell lysates with the protein GlpOD-
FAD had a whitish appearance, like E. coli
BL21(DE3) harbouring vector pETHIS-1 with-
out insert. This indicates that cell lysates with
recombinant GlpO contained protein-bound
ﬂavin (i.e. bound FAD), whereas GlpODFAD
did not bind FAD.
In order to conﬁrm this, ﬂuorescence spectra
of the two recombinant proteins GlpO and
GlpODFAD were measured and compared with
thespectraofanFADsolution,thelatterdisplay-
ing an emission maximum at 525 nm. The ﬂuo-
rescence spectra of recombinant GlpO-samples
displayed the typical protein-derived excitation
maximum at 280 nm and also showed an emis-
sion maximum at 525 nm (Fig. 4), indicating
that recombinant GlpO contained bound FAD
thatmusthavebeenacquiredduringoverexpres-
sion in E. coli. In contrast, ﬂuorescent spectro-
scopic analysis of recombinant GlpODFAD
displayed solely an excitation maximum at
280 nm and no peak visible at 525 nm in the
emission spectrum, showing that this recombi-
nant protein did not contain bound FAD
(Fig. 4). These results indicate that recombinant
GlpODFAD lacking the putative FAD-binding
site Gly12-Gly13-Gly14-Ile15-Ile16-Gly17 was
unable to acquire and bind the cofactor FAD
when expressed in E. coli, hence explaining
why it is enzymatically inactive.
3.4. Neutralising activity of anti-GlpODFAD
antibodies
With respect to future vaccine design, it
appears highly desirable to use enzymatically
Figure 3. Immunoblot detection of GlpO and
GlpODFAD. (A) One-microgram samples of puriﬁed
recombinant GlpO (lane 1) and GlpODFAD (lane 2)
were run by SDS-10% polyacrylamide gels, trans-
ferredontoanitrocellulosemembraneandprobedwith
anti-His antibody. (B) Total antigen (approximately
10 lg per lane) of M. mycoides subsp. mycoides SC
strain Afade ´ was separated on SDS-10% polyacryl-
amide gels and immunoblotted using either anti-GlpO
( l a n e1 )o ra n t i - G l p O DFAD antiserum (lane 2) at a
dilution of 1:1000. Std, molecular mass standards.
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animals able, like those directed against native
GlpO [13], to neutralise GlpO and thereby
obliterating the cytotoxic effect of M. mycoides
subsp. mycoides SC. The neutralising activity
of rabbit antibodies that were induced by immu-
nisation with recombinant GlpODFAD was
therefore assessed.
As observed with rabbit anti-GlpO [13], de-
complemented rabbit anti-GlpODFAD serum
and protein G-puriﬁed IgG prepared thereof
were shown to speciﬁcally block the release
of H2O2 by M. mycoides subsp. mycoides SC
strain Afade ´ grown in liquid medium supple-
mented with 100 lM glycerol. Pre-immune
serum or IgG of the unvaccinated rabbit had
no inhibitory effect. Consequently, the GlpOD-
FAD protein lacking the FAD-binding site and
the native GlpO have similar capacities to
induce GlpO-neutralising antibodies.
In order to evaluate whether anti-GlpOD-
FAD antibodies are also able to neutralise trans-
location of H2O2 and the accompanying oxygen
radicals from M. mycoides subsp. mycoides
SC into ECaNEp cells, and the resulting cyto-
toxic effects, ECaNEp cells were pre-treated
with CM-H2DCFDA to detect intracellular
oxidation of this compound by ﬂuorescence
microscopy. Infection with the African
M. mycoides subsp. mycoides SC ﬁeld strain
Afade ´ produced a strong induction of ﬂuores-
cence in ECaNEp cells 20 min after the addi-
tion of glycerol, reﬂecting the presence of
intracellular H2O2, an event followed by cell
death. No ﬂuorescence was detected in the
control experiment where ECaNEp cells were
infected with the Afade ´ strain without the
addition of glycerol (Fig. 5). Intracellular oxida-
tion of CM-H2DCFDA in ECaNEp cells as
visualised by ﬂuorescence was inhibited when
infecting M. mycoides subsp. mycoides SC
were pre-treated with antibodies directed either
against GlpO (Fig. 5C) or against GlpODFAD
(Fig. 5D). This showed that GlpODFAD is
able to induce antibodies that prevent H2O2
translocation from infecting M. mycoides subsp.
mycoides SC to the host cells.
4. DISCUSSION
With the aim of designing new live vaccines
againstCBPPusingspeciﬁc,targeted,attenuating
mutations in the genome of M. mycoides subsp.
mycoides S C ,w ei n v e s t i g a t e dt h er o l eo ft h e
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Figure 4. Fluorescence excitation and emission spectra of GlpO, GlpODFAD and FAD. Spectra of GlpO
(4.6 lM), GlpODFAD (1.2 lM) and FAD (7.7 lM) in 20 mM PBS were recorded. Excitation wavelength
was 350 nm, and emission wavelength was 430 nm. Excitation spectra were measured at 250–410 nm;
emission spectra were measured at 370–600 nm. The bold line represents the recombinant protein GlpO, the
dashed line represents GlpODFAD and the dotted line represents free FAD.
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oxidase GlpO, a central enzyme for the virulence
of this pathogen [4, 13, 14].
Spectroscopicanalysisrevealedthatthemod-
iﬁed recombinant GlpODFAD – the GlpO
protein-mutant whose FAD-binding site was
knocked out by recombinant gene technology –
was devoid of bound FAD while the intact
recombinant GlpO did contain bound FAD. It
is interesting to note at this point that puriﬁed
recombinant GlpO, in contrast to GlpODFAD,
showed two protein bands on SDS-polyacryl-
amide gels and immunoblots, the larger band
being attributed to the formation of a dimeric
aggregate of GlpO, in accordance with the ﬁnd-
ing that this oxidase is a dimeric protein in other
organisms [6, 7]. The observation that GlpOD-
FAD is present uniquely as a monomer on
immunoblots suggests that the lack of the
FAD-binding site (or the failure of binding
FAD) also changed structural properties of this
protein. Furthermore, the FAD-binding site of
GlpO was demonstrated to play a central role
intheenzymaticactivityoftheoxidase,asshown
bytheinabilityofGlpODFAD to oxidise a-glyc-
erol-3-phosphate (G3P) and to produce toxic
H2O2.
Antibodies that were raised in rabbits against
puriﬁed recombinant GlpODFAD, like anti-
GlpO antibodies, were able to (i) recognise
three bands (representing monomer, dimer and
a possible trimer on immunoblots) of GlpO
from total proteins of M. mycoides subsp. myco-
ides SC; (ii) block the H2O2 production of
M. mycoides subsp. mycoides SC metabolising
glycerol; and (iii) neutralise the resulting cyto-
toxicity towards host cells in an in vitro assay.
Taken together, these results suggest that the
removal of the FAD-binding site from the glpO
gene of M. mycoides subsp. mycoides SC
Figure 5. Fluorescence micrographs showing detection of intracellular H2O2 in ECaNEp cells infected with
M. mycoides subsp. mycoides SC at an MOI of 500 mycoplasmas per cell. ECaNEp cells 20 min after
infection with strain Afade ´ in the absence (A) and in the presence of glycerol (B), or with strain Afade ´ pre-
treated with anti-GlpO IgG (C) or with anti-GlpODFAD IgG (D) in the presence of glycerol.
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of future live vaccines, with preserved capacity
to elicit efﬁcient GlpO-neutralising antibodies
in the host. In order to replace the glpO wild
type gene in the chromosome of M. mycoides
subsp. mycoides SC with the glpODFAD allele
for creation of a targeted deletion mutant, novel,
more powerful methods for allelic replacement
still need to be developed since this organism
does not seem to be particularly apt to homolo-
gous recombination [10].
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